Next Article in Journal
Antibody Response against SARS-CoV-2 after mRNA Vaccine in a Cohort of Hospital Healthy Workers Followed for 17 Months
Next Article in Special Issue
Declining Levels of Neutralizing Antibodies to SARS-CoV-2 Omicron Variants Are Enhanced by Hybrid Immunity and Original/Omicron Bivalent Vaccination
Previous Article in Journal
Human Papilloma Virus Vaccination and Cervical Screening in the Italian Regions: An Overview of the Current State of the Art
Previous Article in Special Issue
Engineered Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2 Omicron Subvariants BA.1, BA.4/5, XBB.1 and BQ.1.1
 
 
vaccines-logo
Article Menu

Article Menu

Article

Article Versions Notes

Vaccines 2024, 12(5), 505; https://doi.org/10.3390/vaccines12050505
Action Date Notes Link
article pdf uploaded. 7 May 2024 15:14 CEST Version of Record https://www.mdpi.com/2076-393X/12/5/505/pdf-vor
article supplementary file uploaded. 7 May 2024 15:14 CEST - https://www.mdpi.com/2076-393X/12/5/505#supplementary
article xml file uploaded 10 May 2024 09:23 CEST Original file -
article xml uploaded. 10 May 2024 09:23 CEST Update https://www.mdpi.com/2076-393X/12/5/505/xml
article pdf uploaded. 10 May 2024 09:23 CEST Updated version of record https://www.mdpi.com/2076-393X/12/5/505/pdf
article html file updated 10 May 2024 09:24 CEST Original file https://www.mdpi.com/2076-393X/12/5/505/html
Back to TopTop